Reviews/Anti CGRP Antibodies/Eptinezumab acute migraine pain freedom
Episodic Migraine · CGRP-EMR-04 · v2
This claim asks whether giving eptinezumab by infusion during a migraine attack makes the pain go away quickly. One large, well-run trial tested exactly this and found that people who got the drug became pain-free sooner than those who got a dummy infusion, with the difference showing up within an hour and being clear by two hours [1][15]. The effect points firmly in the drug's favour and is highly unlikely to be chance. But only about one in four people were fully pain-free at two hours, and the typical time to pain freedom was four hours, so 'rapid' is a generous word [1]. Everything known here comes from that single trial at a single dose, and the trial's own authors say it is not yet clear whether giving this infusion during an attack is even practical [1]. The panel therefore accepted the direction of the claim while holding back because of the single-trial base and the modest size of the benefit.
The RELIEF phase 3 randomized trial [1] gave eptinezumab 100 mg or placebo intravenously within 1 to 6 hours of a moderate to severe attack and met its co-primary time-to-pain-freedom endpoint, with a median of 4 hours versus 9 hours (hazard ratio 1.54, P < .001). At 2 hours, headache pain freedom was reached by 23.5% on eptinezumab versus 12.0% on placebo (P < .001) [1]. An exploratory analysis of the same trial [15] found separation from placebo on pain freedom as early as hour 1 (9.7% versus 4.1%, P < .05), sustained through hour 48. A further post hoc analysis of the identical trial [17] addressed acute-medication optimization rather than pain freedom. No other corpus paper tests eptinezumab given during an attack with a pain-freedom endpoint. The contested point: The division is over the word 'rapid' and the strength of the evidence base: the direction and significance of the pain-freedom effect are undisputed [1][15], but a median of 4 hours and only 23.5% pain-free at 2 hours [1] make the speed modest, and all three supporting papers [1][15][17] are the same single trial, so there is no independent replication.
All 36 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Anti CGRP Antibodies, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
All relevant evidence comes from a single trial (RELIEF, NCT04152083); [1], [15] and [17] are the same study re-analysed, so there is no independent replication of the pain-freedom finding.
'Rapid' is only partly supported: median time to pain freedom was 4 hours and only 23.5% achieved pain freedom at 2 hours, modest relative to standard acute-treatment benchmarks.
Where it remains uncertain. Only 23.5% were pain-free at 2 hours with a 4-hour median [1], and all evidence traces to a single trial at one dose [1][15][17], so both 'rapid' and the robustness of the finding are qualified.
Aleatory
Only 23.5% of treated patients reached pain freedom at 2 hours [1], so outcome for any given attack remains highly variable even under treatment.
The load-bearing papers from a corpus of 36, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Primary RCT evidence that during-attack eptinezumab shortens time to pain freedom
“At 2 hours after infusion, in the respective eptinezumab and placebo groups, headache pain freedom was achieved by 23.5% and 12.0% (between-group difference, 11.6% [95% CI, 4.78%-18.31%]; odds ratio, 2.27 [95% CI, 1.39-3.72]; P < .001)”
Panel auditInternal validity: high · scope of inference: Adults eligible for preventive therapy (4-15 migraine days/month) treated during a moderate-to-severe attack with IV eptinezumab 100 mg.Key limitations: IV administration during attack not practical in routine care · median pain freedom at 4 hours tempers 'rapid' · single dose level · 2-hour pain freedom only 23.5%
Supports the 'rapid' element with early (hour-1) placebo separation on pain freedom
“At hour 1, more eptinezumab-treated patients achieved headache pain freedom (9.7%), headache pain relief (38.7%), and absence of MBS (33.2%) versus placebo (4.1%, 26.9%, and 22.1%, respectively; P < .05 all)”
Panel auditInternal validity: medium · scope of inference: Adults treated during an attack with IV eptinezumab 100 mg; earliest timepoint of separation from placebo.Key limitations: exploratory multiple comparisons · absolute 1-hour pain freedom only 9.7% · IV route impractical acutely · censoring at rescue medication
Outcomes are mTOQ optimization and HIT-6 change, not during-attack pain-freedom rates.
Panel auditInternal validity: medium · scope of inference: Impact of attack-time eptinezumab on subsequent acute-medication optimization over 4 weeks.Key limitations: post hoc · surrogate questionnaire endpoint · no direct pain-freedom result reported
3 of 36 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A pivotal RCT directly supports the claim with high significance, but single-trial dependence, a modest absolute effect, and an unestablished feasibility pathway cap confidence at Likely.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent replication of in-attack pain freedom. The entire claim rests on one trial [1][15][17], so a confirmatory result is the single largest source of remaining uncertainty. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A second, independently conducted randomized placebo-controlled trial of eptinezumab given during an attack with time-to-pain-freedom as a primary endpoint.
Open question: Does the shortened time to pain freedom reproduce in a trial independent of RELIEF? Why it is still open: The only supporting papers [1][15][17] are the same trial, so replication is absent from the corpus.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19